We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sino Biological Logo

Sino Biological

Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones.

Latest Sino Biological Content

A labelled antibody and a cell.
Product News

FDA-Approved TIVDAK®: Targeting Tissue Factor in Cervical Cancer

On April 29th, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.
A scientist using an iPad in a lab.
Product News

Sino Biological Finalizes the Acquisition of SignalChem Biotech

Sino Biological, Inc. ("Sino Biological" or the "Company”), has successfully concluded its acquisition of Vancouver-based Canadian biotechnology company SignalChem Biotech Inc.
The Landscape of Cancer Research: Advances in Immuno-oncology
Online Event

The Landscape of Cancer Research: Advances in Immuno-oncology 2024

Key advances will be highlighted across the field of immuno-oncology. Hear a cross-section of experts discuss their research with a focus on basic research and a broad range of established and novel immunotherapeutics.
Antibodies.
Product News

Therapeutic Potential of CD20 X CD3 Bispecific Antibodies

As of March 2024, the FDA has approved three CD20 × CD3 BsAbs: mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma (R/R FL), glofitamab (Columvi) for relapsed or refractory diffuse B cell lymphoma
Cytokines for BEST Cell Culture
Product
Advertisement

BEST-IN-CLASS Cytokines for BEST Cell Culture

Click here for further information!
Cell and Gene Therapy Symposium, March 20-21: Experts discuss cancer immunotherapy, gene vectors, stem cells, and precision oncology
Online Event

Cell and Gene Therapy 2024

On-Demand
Explore cutting-edge cell and gene therapies at our online symposium on March 20–21. Experts will discuss cancer immunotherapy, gene therapy vectors, stem cells, and precision oncology research.
3D Organoid Research Solutions
Product
Advertisement

3D Organoid Research Solutions

Learn More!
MMPs, Architects of Tumor Microenvironment
Product
Advertisement

MMPs: Architects of Tumor Microenvironment

Learn more about MMPs!
Custom Baculovirus–Insect Cell Protein Expression Service
Product
Advertisement

Custom Baculovirus–Insect Cell Protein Expression Service

Learn more!
Novel CAR Technology To Transform Cancer Therapy
Whitepaper

Novel CAR Technology To Transform Cancer Therapy

Chimeric antigen receptor (CAR) therapies involve the use of engineered receptors capable of redirecting immune cells to recognize and destroy cancer cells expressing a specific antigen. Currently, CAR T cells dominate the field of CAR therapy.
Advertisement